<DOC>
	<DOCNO>NCT02243982</DOCNO>
	<brief_summary>The PET tracer Fluoro-ethyl-methyl-amino-naphthyl-ethylidene-malononitrile ( [ F18 ] -FDDNP ) specific affinity lesion contain tau protein beta-amyloid The study consist two phase - In first transversal phase , 8 neurologically unimpaired control , 15 patient PD dementia ( PDND ) 8 PD dementia ( PDD ) undergo lumbar puncture study tau , phospho-tau beta-amyloid level cerebrospinal fluid ( CSF ) , well positron emission tomography ( PET ) ( [ F18 ] -FDDNP . Concentration CSF marker degree topography FDDNP-PET uptake compare among group , along correlation analysis CSF PET finding . - During second phase ( 18 month follow-up ) , PDND patient undergo procedure , cognitive change include incident dementia assess . The correlation cognitive impairment neurochemical neuroimaging change establish determine predictive value marker . Since pathological lesion observe Alzheimer disease ( AD ) common PD concentration tau beta-amyloid altered AD PET [ F18 ] -FDDNP able separate patient AD cognitive impairment control , hypothesize : 1 . - Patients PD show biomarkers profile similar AD ( decrease level beta-amyloid increase phospho-tau tau ) CSF , abnormal uptake [ F18 ] -FDDNP PET compare PDND patient control . 2 . -The distribution cortical [ F18 ] -FDDNP PD different AD similar dementia Lewy body , predominantly posterior cortical area . 3 . PDND patient show [ F18 ] -FDDNP PET uptake level protein marker CSF intermediate control patient PD . 4 . -In subsequent follow-up , PDND patient show cognitive impairment correlate change level protein marker CSF uptake PET [ F18 ] -FDDNP 5 . - The predictive value development dementia PD specific pattern PET uptake CSF protein profile establish .</brief_summary>
	<brief_title>Predictive Diagnostic Value Tau Beta-amyloid Markers Dementia Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Supranuclear Palsy , Progressive</mesh_term>
	<mesh_term>Radiopharmaceuticals</mesh_term>
	<criteria>Inclusion Criteria PDD Male female ≥ 60 year old ; Diagnose PD probable definite accord criterion United Kingdom Parkinson 's Disease Society Brain Bank ; The Hoehn &amp; Yahr stage disease 3 5 state ; Diagnose dementia establish accord fourth edition Diagnostic Statistical Manual Mental Disorders ( DSMIV ) diagnostic guideline dementia Movement Disorders Society ( MDS ) ; The score MiniMental State Examination Folstein ( MMSE ) &lt; 24 ; The score Mattis Dementia Rating Scale ( MDRS ) &lt; 136 . Inclusion criterion PDND : Male female ≥ 60 year old ; Diagnose PD probable definite accord criterion United Kingdom Parkinson 's Disease Society Brain Bank ; The Hoehn &amp; Yahr stage disease 3 5 OFF state ; The score MiniMental State Examination Folstein ( MMSE ) ≥24 ; The score Mattis Dementia Rating Scale ( MDRS ) ≥136 . Inclusion criterion Controls : Male female ≥ 60 year old ; No know diagnosis neuropsychiatric diseases The score MiniMental State Examination Folstein ( MMSE ) ≥24 ; The score Mattis Dementia Rating Scale ( MDRS ) ≥136 . The subject pregnant breastfeeding ; The subject history drug abuse alcohol ; The subject develop dementia first year parkinsonism parkinsonism ; The subject meet criterion vascular dementia ; The subject symptom suggestive type parkinsonism ( multisystem atrophy corticobasal , supranuclear palsy progressive degeneration ) degenerative dementia ( frontotemporal dementia ) ; The subject moderate severe renal functional impairment ( serum creatinine &gt; 1.5 mg / dL ) ; The subject moderate severe hepatic impairment ( bilirubin &gt; 2 time upper limit normal , transaminases &gt; 3 time upper limit normal ) ; The subject present structural abnormality basal ganglia cortical level magnetic resonance image computerized tomography ; The subject participate clinical study investigational drug product within 30 day prior screen / radiopharmaceutical minimum period 5 radioactive halflives prior screen ; Occupational exposure radiation &gt; 15 milliSievert ( mSv ) / year The subject receive treatment nonsteroidal antiinflammatory drug 30day period PET scan The subject allergy investigational product component ; The subject clinically active , serious disease reduce life expectancy ; The subject claustrophobic / . The subject receive last 364 day dose ionize radiation couple study dose exceed 10 mSv</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Parkinson , dementia , FDDNP , tau , beta-amyloid</keyword>
</DOC>